The Autoinjectors Market is expected to witness a growth rate of 14-16% by 2028. The key factors driving the market are the ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.8, along ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. Just like last year, the Skyrizi and Rinvoq maker scored the highest by far in ZoomRx’s analysis of how healthcare ...

On this episode of Stock Movers: - AbbVie (ABBV) is lower this morning alongside pharma stocks as President plans to order a cut in US prescription drug costs by mandating that Americans pay no ...

adding that as it is aware AbbVie has not pursued the development of any products that use the alleged trade secrets. It also alleges that AbbVie has now filed a series of lawsuits against ...

In 2024 alone, AbbVie earned around $15 billion in revenue from Allergan products. AbbVie didn't stop there. AbbVie acquired ImmunoGen and Cerevel Therapeutics in 2024 for $10 billion and $9 ...

As of 2024, the drug device combination products market was dominated by Abbott (US), Boston Scientific Corporation (US), ...

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and ...

Gubra AS (NASDAQ COPENHAGEN:GUBRA) presented its first quarter 2025 results on May 9, highlighting a transformative partnership with AbbVie (NYSE:ABBV) and progress in its innovative obesity ...